Adynxx Sub, Inc.
Records under this name other than patents Adynxx Sub, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,041,069 | Gene Expression and Pain now held by Vyripharm Enterprises, Inc. In force · High confidence | In force | High confidence | |
| US 8,741,864 | Gene Expression and Pain now held by Vyripharm Enterprises, Inc. Lapsed on the fee record Ended Jun 3, 2026 · High confidence | Lapsed on the fee record | Ended Jun 3, 2026 | High confidence |
| US 10,683,502 | Oligonucleotide Decoys for the Treatment of Pain now held by Vyripharm Enterprises, Inc. Lapsed on the fee record Ended Jun 16, 2024 · Medium confidence | Lapsed on the fee record | Ended Jun 16, 2024 | Medium confidence |
| US 9,290,762 | Gene Expression and Pain now held by Vyripharm Enterprises, Inc. Lapsed on the fee record Ended Mar 22, 2024 · High confidence | Lapsed on the fee record | Ended Mar 22, 2024 | High confidence |
| US 8,093,225 | Gene Expression and Pain now held by Vyripharm Enterprises, Inc. Lapsed on the fee record Ended Jan 10, 2024 · High confidence | Lapsed on the fee record | Ended Jan 10, 2024 | High confidence |
| US 10,434,178 | Formulations for the Delivery of Active Ingredients now held by Vyripharm Enterprises, Inc. Lapsed on the fee record Ended Oct 8, 2023 · High confidence | Lapsed on the fee record | Ended Oct 8, 2023 | High confidence |
| US 7,943,591 | Gene Expression and Pain now held by Vyripharm Enterprises, Inc. Lapsed on the fee record Ended May 17, 2023 · High confidence | Lapsed on the fee record | Ended May 17, 2023 | High confidence |
| US 10,287,583 | Oligonucleotide Decoys for the Treatment of Pain now held by Vyripharm Enterprises, Inc. Lapsed on the fee record Ended May 14, 2023 · High confidence | Lapsed on the fee record | Ended May 14, 2023 | High confidence |
| US 9,700,624 | Formulations for the Delivery of Active Ingredients now held by Vyripharm Enterprises, Inc. Lapsed on the fee record Ended Jul 11, 2021 · High confidence | Lapsed on the fee record | Ended Jul 11, 2021 | High confidence |
| 16/080,547 | Compositions and Methods for Pain Amelioration via Modification of Gene Expression now held by Vyripharm Enterprises, Inc. Abandoned Abandoned Oct 13, 2021 | Abandoned | Abandoned Oct 13, 2021 |